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METHODS
Pancreatic ductal adenocarcinoma (PDAC) is a recalcitrant cancer 
and a leading cause of cancer-related death in the United States, 
with a long-term survival rate of just under 10% [1]. Chemotherapy 
is one of the standard treatment options for pancreatic cancer; 
however, rapid development resistance to chemotherapeutic 
agents represents a significant bottleneck. Therefore, identifying 
novel biological drug targets and exploring biomolecular 
mechanisms that lead to chemoresistance in pancreatic cancer is 
urgently required.  Lactate dehydrogenase A (LDHA): the primary 
metabolic enzyme that facilitates the glycolytic process by rapidly 
converting pyruvate to lactate. The overexpression of LDHA is 
common in malignant cancers. [2,3]. Multiple studies have shown 
that LDHA plays an important role in the growth, invasion and 
metastasis of these malignant tumors [4]. As LDHA expression 
increases, lactate concentration in the tumor microenvironment 
(TME) increases as well.  By exploiting aerobic glycolysis, cancer 
cells secrete high amounts of lactate that is then used for diverse 
functions that support cell proliferation and resistance [5].
 [4] FIGURE 1:  Lactate produces many intermediates that promotes 
cancer cell growth.  The increased production of lactate promotes 
acidosis in TME which favors angiogenesis and metastasis. It favors 
immunosuppression by inhibition of T cell lymphocytes. Lactate can 
enter the TCA cycle where it participates in generation of many TCA 
intermediaries that can then be used as fuel.
RESULTS
❑ We evaluated the mechanisms behind the anticancer activity of 
a novel LDHA inhibitor 23 in pancreatic cancer cell lines.
❑ We performed Western blot analysis of Mia-Paca2 cells treated 
with compound 23 for 24 h.
❑ We found that the LDHA-inhibitor, inhibited the activity of 
LDHA(data not shown), without affecting  its the expression.
❑ Western blot analysis revealed activation of proapoptotic 
proteins, like cleaved poly (ADP-ribose) polymerase (PARP), 
cleaved Caspase 9 while the expression of the anti-apoptotic 
protein, B-cell lymphoma 2 (Bcl-2) was decreased by the 
LDH-A-inhibitor.
❑ Actin was used as a loading control.
REFERENCES
BACKGROUND
This work was supported by Guy Hagin Endowment Fund and 
College of Arts and Science Grant.
Cell Culture: MIA PaCa-2 cell were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM) supplemented with 10% fetal 
bovine serum and  2.5% , horse serum at 37°C in a 5% CO2 
atmosphere.
FIGURE 3: Cell Treatment 
Methods:  MIA PaCa-2 
cells were seeded in 6-well 
plates overnight, next day 
medium was replaced with 
serum free medium, and 
cells were treated with 
50uM concentration of the 
LDH-A-inhibitor for 24 
hours.
Protein extraction: 
Cells were lysed using ice-cold RIPA buffer supplemented with 
protease inhibitors by using gentle scrapping. Lysate was incubated 
(4°C, 20 min), and then centrifuged (15,000g, 20 min, 4°C) to 
collect the total proteins. Total protein in cell lysates was measured 
by the bicinchoninic acid method.
Immunoblotting:
Equal amounts of protein from each sample were loaded on a 
NuPAGE Bis-Tris Gels (4-12% gradient gel) and transferred to 
polyvinylidene fluoride membrane. The membranes were incubated 
with appropriate primary and secondary antibodies. 
Immunoreactive proteins were detected using Luminata Forte 
Western HRP Substrate and quantified. . Antibodies for LDHA 
(#3582), Actin ( #3700), and apoptosis sampler kit  (#9915.) were 
purchased from Cell Signaling Technology.
Figure 4: Mia-Paca2 Cells 
were treated with  50 µm 
concentration of LDH-A 
inhibitor. DMSO was used as 
the control. The cells were 
lysed, and the expression of 
proteins related with 
apoptotic pathway was 
examined by western blot 
analysis.
Treatment of Mia-PaCa2 cells with LDH-A Inhibitor (Compound 23) 
Promotes Apoptosis: 
❑ Our initial findings suggest that the antiproliferative effect  of 
LDHA inhibitor 23 in pancreatic cancer cells are due to induction 
of apoptosis.
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FIGURE 2: Culturing of MIA PaCa-2
OBJECTIVES
❑ To understand the molecular mechanisms underlying the 
anticancer activity of a novel LDHA inhibitor, compound 23, in 
pancreatic cancer cell lines.
❑ To determine if  LDHA inhibitor, compound 23 promotes cancer 
cell death via inducing apoptosis.
